Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:43 PM
Ignite Modification Date:
2025-12-24 @ 2:43 PM
NCT ID:
NCT05326659
Eligibility Criteria:
Inclusion Criteria:
* Age 18\~65 years.
* Patients who were treated with Benvitimod cream and have discontinued medication were again diagnosed as suitable for treatment with Benvitimod cream.
* The participant with diagnosis of mild to moderate stable psoriasis vulgaris:
* BSA \< 10%.
* PGA ≥ 2.
* Capable of giving written informed consent.
Exclusion Criteria:
* ALT/AST \> 3 ULN, BUN/Cr \> 1.5 ULN.
* Skin lesions were limited to head，face and skin folds.
* Women who are pregnant, breast-feeding, or planning to become pregnant.
* Known to be allergic to active ingredients or any of the components of the drug.
* Alcoholic, or regular use of Chinese herbs or sedatives, sleeping pills, tranquilizers and other addictive drugs.
* Subjects who have other conditions that may interfere with the evaluation of the efficacy of psoriasis and/or other serious skin diseases other than psoriasis.
* Subjects who have serious diseases of the central nervous system, cardiovascular system, kidney, liver, digestive tract, respiratory system, metabolism and skeletal muscle system.
* Subjects who were considered unsuitable to participate in the study by the investigators.
* Received uv phototherapy, photochemotherapy, or systemic therapy (e.g., systemic glucocorticoid, methotrexate, retinoic acid, or cyclosporine) within 4 weeks prior to baseline visit.
* Received topical anti-psoriasis therapy (including topical glucocorticoids, retinoids, vitamin D analogues, or calcineurin inhibitors) within 2 weeks prior to baseline visit, except where the site of administration was not the target lesion after enrollment.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT05326659
Study Brief:
Protocol Section:
NCT05326659